Literature DB >> 22483359

Immunotherapy: a useful strategy to help combat multidrug resistance.

Tyler J Curiel1.   

Abstract

Multidrug resistance (MDR) renders cancer cells relatively invulnerable to treatment with many standard cytotoxic anti-cancer agents. Cancer immunotherapy could be an important adjunct for other strategies to treat MDR positive cancers, as resistance to immunotherapy generally is unrelated to mechanisms of resistance to cytotoxic agents. Immunotherapy to combat MDR positive tumors could use any of the following strategies: direct immune attack against MDR positive cells, using MDR as an immune target to deliver cytotoxic agents, capitalization on other immune properties of MDR positive cells, or conditional immunotoxins expressed under MDR control. Additional insights into the immunogenic potential of some cytotoxic agents can also be brought to bear on these strategies. This review will highlight key concepts in cancer immunotherapy and illustrate immune principles and strategies that have been or could be used to help destroy MDR positive tumor cells, either alone or in rational combinations.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22483359      PMCID: PMC4226134          DOI: 10.1016/j.drup.2012.03.003

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN: 1368-7646            Impact factor:   18.500


  68 in total

Review 1.  Cancer stem cells: mirage or reality?

Authors:  Piyush B Gupta; Christine L Chaffer; Robert A Weinberg
Journal:  Nat Med       Date:  2009-09-04       Impact factor: 53.440

2.  Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8⁺ T cells.

Authors:  Carmen Visus; Yangyang Wang; Antonio Lozano-Leon; Robert L Ferris; Susan Silver; Miroslaw J Szczepanski; Randall E Brand; Cristina R Ferrone; Theresa L Whiteside; Soldano Ferrone; Albert B DeLeo; Xinhui Wang
Journal:  Clin Cancer Res       Date:  2011-08-19       Impact factor: 12.531

3.  Regulation of the hepatic multidrug resistance gene expression by endotoxin and inflammatory cytokines in mice.

Authors:  G Hartmann; H Kim; M Piquette-Miller
Journal:  Int Immunopharmacol       Date:  2001-02       Impact factor: 4.932

4.  Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2.

Authors:  Yuxian Huang; Yang Wang; Yuhua Li; Kunyuan Guo; Yanjie He
Journal:  J Cancer Res Clin Oncol       Date:  2010-09-01       Impact factor: 4.553

5.  Combined immunochemotherapy in selected patients with metastatic renal cell carcinoma: HLA class II genotype can help to predict response to therapy.

Authors:  Stefan Bierer; Ina Hoffmeister; Joachim Gerss; Edwin Herrmann; Christian Wülfing; Walter Sibrowski; Lothar Hertle; Reinhard Kelsch
Journal:  J Immunother       Date:  2011-03       Impact factor: 4.456

6.  Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan.

Authors:  R Komdeur; B E Plaat; H J Hoekstra; W M Molenaar; H Hollema; E van den Berg; M F Mastik; W T van der Graaf
Journal:  Cancer       Date:  2001-05-15       Impact factor: 6.860

Review 7.  Tregs and rethinking cancer immunotherapy.

Authors:  Tyler J Curiel
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 8.  Glioma stem cell research for the development of immunotherapy.

Authors:  Jianfei Ji; Keith L Black; John S Yu
Journal:  Neurosurg Clin N Am       Date:  2010-01       Impact factor: 2.509

Review 9.  Immunogenicity of anthracyclines: moving towards more personalized medicine.

Authors:  Lionel Apetoh; Grégoire Mignot; Theocharis Panaretakis; Guido Kroemer; Laurence Zitvogel
Journal:  Trends Mol Med       Date:  2008-03-18       Impact factor: 11.951

10.  Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways.

Authors:  X F Hu; J Li; E Yang; S Vandervalk; P X Xing
Journal:  Br J Cancer       Date:  2007-03-06       Impact factor: 7.640

View more
  9 in total

Review 1.  Clinically feasible approaches to potentiating cancer cell-based immunotherapies.

Authors:  V I Seledtsov; A G Goncharov; G V Seledtsova
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  Cancer Stem Cells: Acquisition, Characteristics, Therapeutic Implications, Targeting Strategies and Future Prospects.

Authors:  Anoop K Yadav; Neetin S Desai
Journal:  Stem Cell Rev Rep       Date:  2019-06       Impact factor: 5.739

3.  Identification of an HLA-A2-restricted CD147 epitope that can induce specific CTL cytotoxicity against drug resistant MCF-7/Adr cells.

Authors:  Chuang Qu; Shuhui Gao; Hongwei Shao; Wenfeng Zhang; Huabben Bo; Xin Lu; Tianjiao Chen; Jing Kou; Yue Wang; Gui Si Chen; Shulin Huang; Han Shen
Journal:  Oncol Lett       Date:  2018-02-16       Impact factor: 2.967

4.  Stage IV gastric cancer successfully treated by multidisciplinary therapy including chemotherapy, immunotherapy, and surgery: a case report.

Authors:  Makoto Kawamoto; Hideya Onishi; Norihiro Koya; Hiroyuki Konomi; Kenji Mitsugi; Risa Tanaka; Junichi Motoshita; Takashi Morisaki; Masafumi Nakamura
Journal:  Surg Case Rep       Date:  2017-10-23

Review 5.  Nanomaterials for modulating innate immune cells in cancer immunotherapy.

Authors:  Quoc-Viet Le; Geon Yang; Yina Wu; Ho Won Jang; Mohammadreza Shokouhimehr; Yu-Kyoung Oh
Journal:  Asian J Pharm Sci       Date:  2018-08-23       Impact factor: 6.598

Review 6.  Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches.

Authors:  Talha Bin Emran; Asif Shahriar; Aar Rafi Mahmud; Tanjilur Rahman; Mehedy Hasan Abir; Mohd Faijanur-Rob Siddiquee; Hossain Ahmed; Nova Rahman; Firzan Nainu; Elly Wahyudin; Saikat Mitra; Kuldeep Dhama; Mahmoud M Habiballah; Shafiul Haque; Ariful Islam; Mohammad Mahmudul Hassan
Journal:  Front Oncol       Date:  2022-06-23       Impact factor: 5.738

Review 7.  Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice.

Authors:  Wolf-Dieter Janthur; Nathan Cantoni; Christoph Mamot
Journal:  Int J Mol Sci       Date:  2012-11-28       Impact factor: 5.923

Review 8.  Understanding and targeting cancer stem cells: therapeutic implications and challenges.

Authors:  Ke Chen; Ying-hui Huang; Ji-long Chen
Journal:  Acta Pharmacol Sin       Date:  2013-05-20       Impact factor: 6.150

9.  Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer.

Authors:  Sukeshi Patel; Vincent Hurez; Steffan T Nawrocki; Martin Goros; Joel Michalek; John Sarantopoulos; Tyler Curiel; Devalingam Mahalingam
Journal:  Oncotarget       Date:  2016-09-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.